Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Common heart drug may stop deadly bleeding in liver patients

NCT ID NCT05872698

Disease control Sponsor: King's College Hospital NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether beta-blockers, a type of blood pressure medicine, can reduce the risk of bleeding from small varices in people with cirrhosis and portal hypertension. About 763 adults with small varices will receive either beta-blockers or a placebo for up to 3 years. The goal is to see if the drug lowers the chance of serious liver complications like bleeding or liver failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

763 people

The number who actually took part.

Started

Apr 2019

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years and over * Cirrhosis and portal hypertension, * Small oesophageal varices diagnosed within the last 6 months, defined as ≤5 mm in diameter or varices which completely disappear on moderate insufflation at gastroscopy. * Not received a beta-blocker in the last week * Capacity to provide informed consent Exclusion Criteria: * Non-cirrhotic portal hypertension * Medium/large oesophageal varices (current or history \[decreasing in size without curative therapy\]), defined as \>5 mm in diameter * Gastric (IGV and GOV2), duodenal, rectal varices with or without evidence of recent bleeding. * Previous variceal haemorrhage * Previous band ligation or glue injection of oesophageal and/or gastric varices * Red signs accompanying varices at endoscopy * Known intolerance to beta blockers * Contraindications to beta blocker use * Unable to provide informed consent * Child Pugh C cirrhosis * Already receiving a beta-blocker for another reason that cannot be discontinued * Graft cirrhosis post liver transplantation * Evidence of active malignancy without curative therapy planned * Pregnant or lactating women * Women of child bearing potential not willing to use adequate contraception during the period of IMP dosing, if relevant * Patients who have been on a CTIMP within the previous 3 months * Clinical symptoms consistent with COVID-19

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cirrhosis, liver are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver esophageal varices portal hypertension esophageal varices with bleeding prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cirrhosis, liver Portal hypertension Variceal hemorrhage Varices, esophageal

Contacts and locations

Locations

  • King's College Hospital

    London, London, SE5 9RS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.